Survodutide improves MASH without worsening of fibrosis in more than 64% at 48 weeks

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.
“I am particularly excited about the findings of the phase 2 trial in survodutide, which demonstrate the potential for glucagon agonism, in addition to GLP-1, to both improve MASH and shift the needle on fibrosis,” Arun Sanyal, MD, professor of medicine, physiology and molecular pathology at Virginia Commonwealth University School of Medicine, said in a related Boehringer Ingelheim

Survodutide was superior to placebo and significantly improved markers of metabolic dysfunction-associated steatohepatitis without worsening of fibrosis, according to data presented at EASL Congress.
“I am particularly excited about the findings of the phase 2 trial in survodutide, which demonstrate the potential for glucagon agonism, in addition to GLP-1, to both improve MASH and shift the needle on fibrosis,” Arun Sanyal, MD, professor of medicine, physiology and molecular pathology at Virginia Commonwealth University School of Medicine, said in a related Boehringer Ingelheim